Background: Clinical guidelines for cervical cancer screening have incorporated comparative risks of cervical intraepithelial neoplasia grade 3 or cancer (CIN3
Introduction
In the United States, cervical cancer incidence has been dramatically reduced through widespread implementation of frequent cervical cytology using Papanicolaou (Pap) testing. With the increased understanding of the natural history of cervical carcinogenesis, biomarkers are emerging that might better stratify the risk of cervical precancer (cervical intraepithelial neoplasia grade 3) and cancer (CIN3 þ ) and reduce frequency of screening. As professional societies consider how to incorporate new biomarkers such as human papillomavirus (HPV) testing into cervical cancer screening and management, they are using comparative risks of CIN3 þ to help determine management recommendations in practice guidelines. In 2013, the American Society for Colposcopy and Cervical Pathology (ASCCP) created management guidelines for women with abnormal cervical screening results (1) . Using the principal of "equal management of women with equal risks" (2), the risks of CIN3 þ and cancer were compared between women with different screening results to determine appropriate management. Although the management of high-grade cytologic abnormalities (immediate colposcopic referral) is rather noncontroversial, determining appropriate management of negative or mildly abnormal (i.e., ASC-US HPV þ , or LSIL) screening results has been more complicated. Unfortunately, because very large populations with long-term follow-up are needed, it can be difficult to obtain precise risk estimates for negative and mildly abnormal cervical screening results that carry a low risk of CIN3 þ . Large longitudinal cohorts are ideal because they are sufficiently powered to detect CIN3 þ at sequential screening rounds. For the ASCCP management guidelines review, data were primarily considered from one source, that is, from women undergoing cervical screening at Kaiser Permanente Northern California (KPNC), a large integrated health delivery system that has practiced standardized routine cotesting (cervical cytology and HPV testing together) since 2003 (3). However, the application of risk assessment for benchmarking for cervical cancer screening has not been entirely straightforward because absolute risk estimates after negative and mildly abnormal screening results have differed between KPNC and two large U.S. randomized controlled trials, the Atypical Squamous Cells of Undetermined Significance (ASCUS)/LSIL Triage Study (ALTS) and the Addressing the Need for Advanced HPV Diagnostics (ATHENA) study (3) (4) (5) . The reasons for these differences are not certain, but might relate to the differences between population-based screening cohorts and clinical trials. Therefore, risk estimates in other large population-based cohorts are critically needed.
The 
Materials and Methods

Registry
The NMHPVPR is a public health surveillance activity established to evaluate the continuum of cervical cancer prevention throughout the state. The structure of the NMHPVPR has been described previously (7 Cervical cytology and HPV results were ascertained for the period January 1, 2007, to December 31, 2011, from nine laboratories in New Mexico and nine out-of-state laboratories that serve New Mexico residents. All hospitals and clinical practices in New Mexico report through these laboratories. Probabilistic matching and linking of different tests to the same woman was performed and augmented by manual reviews when linkage was uncertain (8).
Study population and outcomes
Our analysis included women ages 21 to 64 with a negative, ASC-US or LSIL baseline cervical screening result reported during January 1, 2007, to December 31, 2011. Women were excluded if records indicated that they had a prior cervical cytology within 300 days of their baseline screening cytology (suggesting that the baseline test was a follow-up rather than screening test) or if they had a cervical excisional procedure (i.e., loop electrosurgical excisional procedure [LEEP] or cone biopsy) or hysterectomy, prior to their baseline screening cytology (7, 9) . Women with an abnormal baseline cytology and no subsequent follow-up were excluded from all analyses. Women were followed through electronic and paper medical records submitted to the NMHPVPR (10). The outcomes were defined by local community readings of histopathology results from biopsy, endocervical curettage, excisional procedure, or hysterectomy without central review from the date of baseline screening through December 31, 2013. An outcome of cervical intraepithelial neoplasia (CIN) grade 2 or worse (CIN2 þ ) included results of CIN1-2, CIN2, CIN2-3, CIN3, CIS, adenocarcinoma in situ (AIS), squamous-cell carcinoma, or high grade (not otherwise specified [NOS] ). An outcome of CIN3 þ was defined as a result of CIN2-3, CIN3, CIS, AIS, or squamous-cell carcinoma. Adenocarcinomas (n ¼ 114) were excluded from this report due to ongoing work related to potential misclassifications of cervical and endometrial adenocarcinomas. Follow-up for outcomes was terminated at the date of an excisional procedure, or hysterectomy.
Statistical methods
We estimated the cumulative incidence of histological outcomes of CIN2 þ and CIN3 þ for each cervical cytology result (normal, ASC-US or LSIL). We concentrate on risk of CIN3 þ whereas CIN2 þ , a less reproducible diagnosis of precancer, is included for completeness. We also calculated risks for women with ASC-US and a concurrent HPV test result (ASC-US/HPVpositive or ASC-US/HPV-negative). We compared two different analytic approaches to validate the conclusions.
First, we used the standard KM approach commonly used in these analyses (11) (12) (13) (2, 6) and Supplementary Materials to this paper. The cumulative risk was calculated as the sum of risk at the baseline cervical cytology (plotted at time zero on each figure) and the incidence after baseline. For nonnegative baseline cervical cytology results, the risk at baseline was computed as the proportion of all women with a histologic diagnosis of CIN2 þ or CIN3 þ on or after the baseline cytology test and before any subsequent screening cytology test, negative follow-up cytology, Separate models, from both approaches, were fit for each cervical screening result (negative, ASC-US, LSIL, HPV-positive/ ASC-US, and HPV-negative/ASC-US) among women in 5-year age groups (21-24, 25-29 years, etc.). This age range was selected for comparison with similar population-based analyses of risk in the United States (2) . Five-year cumulative risk estimates were compared between cervical screening results using a two-sample zstatistic on the complementary log-log scale transformed cumulative risk. We used weighted least squares regression on the complementary log-log scale transformed logistic-Weibull estimates of 5-year cumulative risk to compute a test for trend across age groups (21-29, 30-39, 40-49, and 50-64). SAS version 9.3 was used for all analyses. P value of <0.05 was considered statistically significant. biopsy, excisional procedure, or hysterectomy) beyond the baseline screening cytology. Women with an HPV-positive/ASC-US or LSIL cytology were more likely to have follow-up data. Stratified analyses showed that among women with a negative screening result, those age 50 to 64 were also less likely to have follow-up data. This might be due to less frequent screening at older ages or incomplete ascertainment of hysterectomy. Patterns of follow-up by age and cytology were not confounded by year of baseline cytology. For the other 325,485 women, the mean follow-up time was 3.69 years (SD ¼ 1.69, median ¼ 3.83, IQR ¼ 2.32-5.10). The total follow-up time was 1,201,734 person-years. Women with an LSIL or HPV-positive/ASC-US result were more likely to be in the youngest age categories (age 21-29) compared to women with an HPV-negative/ASC-US or cytology-negative result (59.3% vs. 25.9%, P < 0.001).
Results
Between
The cumulative risks of CIN2 þ and CIN3 þ among women ages 21 to 64 years are plotted in Fig. 1A screening results"), the 5-year CIN3 þ risks declined steadily with age. CIN2 þ risks followed a similar age trend across screening results with the exception of women testing HPV-negative/ASC-US, where the decline of risk with older age was statistically significant (logistic-Weibull model, P ¼ 0.03).
Discussion
The results from our analysis of 5-year risk of CIN2 þ and extends to a state-wide population-based evaluation, the strong risk stratification provided by HPV triage of ASC-US cytology (3) (4) (5) 16) . The CIN3 þ risk among women with HPV-positive/ ASC-US screening cytology is similar to risks among women with an LSIL screening cytology whereas the risk among women with HPV-negative/ASC-US screening cytology approximates the risk among women with a negative screening cytology. This trend was consistently observed across all ages with the exception of women age 50 to 64 with an LSIL screening cytology for whom the risk was closer to risks after a negative screening cytology. Because the CIN3 þ risks for the screening cytology results at NMHPVPR had a similar hierarchical ranking to the CIN3 þ risks observed for the same screening cytology results in other cohorts (3) (4) (5) , the risk benchmarking methodology when applied across cohorts will apparently result in the same patient management recommendations. As seen in other cohorts, the cumulative CIN2 þ and CIN3 þ risks following negative or mildly abnormal cytology results either declined or remained constant with increasing age (3). The observed decline in risk among older women, particularly those approaching the age of menopause and later, should be considered cautiously as CIN2 and CIN3 þ can be more challenging to detect among older women (17, 18) . In addition, although the analysis corrected for benign hysterectomy, ascertainment of hysterectomy data was likely incomplete. The CIN3 þ risk associated with LSIL cytology was notably lower among women ages 50 to 64 years. This may be partially explained by the observed lower HPV positivity rate among women age 45 and older (19) , but HPV testing results are not routinely available as they would be if women were undergoing cotesting, which was uncommon in New Mexico during the period of study (7) . NMHPVPR represents a typical opportunistic screening scenario common to the United States, with great diversity in health plans, clinical practice settings, providers, and patients. By nature, the NMHPVPR state-wide setting includes great variability in patient management, pathology, and HPV laboratories (20) . Higher CIN3 þ risks have been observed in screening trials of HPV-based screening (4, 21, 22) . This might be caused by better immediate disease ascertainment including the greater intensity of follow-up and more frequent sampling and random biopsy in screening trials compared with routine clinical management in NMHPVPR, different population characteristics or random variation. Our analysis explored two different approaches to risk estimation of CIN2 þ and CIN3 þ after screening. As expected, the KM estimates of immediate risk were lower because they are measuring time to detection of CIN rather than time of occurrence. It is uncertain to what extent the logistic-Weibull estimates were precise in estimations of baseline risk. Fortunately, both methods had similar estimates by year 3 in our analyses. One limitation of both the KM and logistic-Weibull risk estimations is that they do not account for any change in the natural history of disease associated with any intervention; for example, disease modification by procedures associated with biopsy and treatment of CIN1 or CIN2 (23).
In conclusion, our analysis of 5-year cumulative CIN2 þ and CIN3 þ risks by baseline screening results from the NMHPVPR confirms and extends the hierarchy of risks observed in other United States screening cohorts (3-5) and our data 
